slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 69,001-69,030
Pages 3,679
Rows per page 30
Component
69,001-69,030 of 110,355
20
The heatmaps visualize EEG frequency power over time, with red indicating high power (arousal) and blue indicating low power.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
21
The slide uses a process flow diagram to show the progression of clinical trials.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Loop · Quick Win Big Bet1 hit
22
The slide outlines a two-stage clinical development process with specific objectives and assessment criteria for each phase.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Loop · Quick Win Big Bet1 hit
24
The slide outlines the core assets (nemvaleukin alfa, IL-12, IL-18) and the strategic rationale for a spin-off.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
25
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) across various cancer types.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
26
The slide uses a matrix-like layout to categorize studies by 'Potential Registration Enabling Studies' and 'Alternative Dosing Studies'.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
28
The slide outlines the strategic rationale for a spin-off, emphasizing focus and profitability.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
30
Includes disclaimer regarding non-GAAP reconciliation and specific business context (oncology spin-off, INVEGA royalties).Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
31
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
07
The slide uses a bulleted list to define the target audience persona.Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · Market Size1 hit
08
The slide uses a survey by BCG to validate brand strength and identify a specific operational bottleneck (inventory availability).Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
11
Uses a before-and-after framing to illustrate the shift in market conditions.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
The slide uses a narrative structure: problem (bank decline) leading to solution (private credit filling the void).Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
13
The slide uses two charts to demonstrate the decline of active management: a bar chart showing increasing underperformance over time and a line chart showing the divergence in fund flows.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
16
The slide uses a stacked bar chart to illustrate a structural shift in investment strategy.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · Solution1 hit
17
Uses bubble charts to visually represent market size disparity.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · Solution1 hit
18
The slide highlights the 'skin in the game' aspect of the firm's investment strategy.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · Solution1 hit
26
Slide 26 of the deck.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
33
The chart uses a waterfall-like structure to decompose 100% of liabilities into four distinct categories.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
35
The chart uses a combination of a line chart for policyholder withdrawals and a bar chart for contractual withdrawals to show historical trends.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
36
The chart uses a shaded region to denote the GFC period (roughly 2Q08 to 1Q09).Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
48
The slide acts as a transition or hub to team-related content.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · Team1 hit
03
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
05
The chart uses a Gantt-style visualization to represent drug development stages.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Problem1 hit
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
Data presented at EASL 2022 and AASLD 2022.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
16
Data presented at AASLD 2022.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
18
The slide outlines a clinical trial design with two main arms involving AB-729, VTP-300, and optional Nivolumab.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit